NCT05683717View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 30, 2028

Conditions
B-Cell Malignancies
Interventions
DRUG

TT-01488 Tablets

TT-01488 tablet will be administered orally once daily per protocol defined schedule.

Trial Locations (1)

210000

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

TransThera Sciences (Nanjing), Inc.

INDUSTRY